Breaking News
Sort by:
Top Post
UltraSight Receives CE Mark for Novel Cardiac AI Technology
UltraSight, an Israeli-based digital health pioneer transforming cardiac imaging through the power of artificial intelligence, […]
£30m for Scientists to Rewrite DNA to Cure Killer Heart Diseases
An injectable cure for inherited heart muscle conditions that can kill young people in the […]
Caption Health and Heartbeat Health Partner to Provide Unprecedented Access to Cardiac Care
Caption Health, the leader in providing services and AI to improve heart ultrasound access, and […]
Acticor Biotech Obtains "PRIME" Status From the European Medicines Agency for Glenzocimab in the Treatment of Stroke
ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the […]
Retia Medical Raises $15 Million to Accelerate Commercialization of the Argos Hemodynamic Monitor
Retia Medical, an innovator in advanced hemodynamic monitoring, today announced that it has secured $15 million in […]
Ai-powered Drug Discovery Company Healx Opens New Labs at Chesterford Research Park
Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery for rare […]
Novartis Pharmaceuticals UK Launches World-first Health-tech Investor Partnership to Reimagine Cardiovascular Care
Novartis Pharmaceuticals UK announces the launch of the Novartis Biome UK Heart Health Catalyst 2022, […]
Centerline Biomedical Raises $33 Million in Series B Financing
Centerline Biomedical, Inc. (Centerline), a private medical technology company, announced the closing of a $33 million Series […]
New Understanding of Congenital Heart Disease Progression Opens Door to Improved Treatment Options
A team of investigators from Texas Heart Institute, Texas Children’s Hospital and Baylor College of Medicine uncovered […]
Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis
Elucid, a company developing a novel, non-invasive medical software to comprehensively characterize cardiovascular disease, announced […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more